Novartis Shares Decline Following Multiple Clinical Trial Setbacks

2026-09-08

The BareStory

Shares of Novartis fell nearly 9% on Tuesday following the announcement that its experimental drug del-desiran failed to meet its primary objective in a late-stage clinical trial. The global phase III study evaluated the treatment in patients with myotonic dystrophy type 1, a muscle-wasting condition, but the therapy did not achieve a statistically significant improvement over a placebo in measuring hand opening times. Novartis stated it is reviewing the data and will consult regulatory authorities regarding potential next steps.

The outcome marks the pharmaceutical company's third major pipeline setback in quick succession. Days earlier, Novartis disclosed that pelacarsen, a cardiovascular drug co-developed with Ionis Pharmaceuticals to lower lipoprotein(a), failed to significantly reduce cardiovascular event risks in late-stage testing. In addition, the company recently paused eight clinical trials for its experimental cell therapy rap-cel after three patients died.

The trial failures have prompted scrutiny from market analysts regarding the company's long-term revenue pipeline, particularly following its approximately $12 billion acquisition of Avidity Biosciences last year to acquire del-desiran. Analysts noted that del-desiran and pelacarsen had represented billions of dollars in projected peak annual sales intended to offset upcoming patent expirations on major medications.

Novartis reaffirmed its financial guidance, maintaining a projected average annual sales growth rate of 5% to 6% through 2030. The company also recently reported positive late-stage trial results for remibrutinib, an experimental treatment that demonstrated a clinically meaningful delay in disability progression for patients with relapsing multiple sclerosis.

Left Perspective

Reckless Capital Allocation Gambles
Alarming Patient Safety Precedents
Fragile Monopoly Replacement Models

Right Perspective

Calculated High-Risk Innovation Engine
Diversified Portfolio Resilience Shield
Efficient Capital Price Discovery

Left Perspective

• Reckless Capital Allocation Gambles High-stakes corporate acquisitions often prioritize defensive revenue replacement over sustainable development. The loss from the approximately $12 billion acquisition of Avidity Biosciences to acquire del-desiran illustrates the hazard of buying expensive assets solely to backfill impending patent expirations. Relying on massive financial consolidation to sustain top-line growth exposes systemic vulnerabilities when unproven therapies fail late-stage clinical trials.

• Alarming Patient Safety Precedents Aggressive pipeline development must never compromise clinical safeguards or ethical standards. The suspension of eight clinical trials for rap-cel following three patient deaths signals an urgent need for stricter oversight of experimental platforms. When commercial pressure mounts to replace falling revenues, the risks of rushing cell therapies through testing pipelines multiply significantly.

• Fragile Monopoly Replacement Models The traditional pharmaceutical business model relies too heavily on securing prolonged monopoly pricing to offset patent cliffs. With multiple trial setbacks across del-desiran, pelacarsen, and rap-cel, the strategy of leaning on speculative, high-cost therapies to deliver billions in peak sales shows its inherent instability. Maintaining long-term corporate growth forecasts while fundamental pipeline assets collapse reveals a disconnect between financial assurances and operational reality.

Right Perspective

• Calculated High-Risk Innovation Engine Breakthrough biopharmaceutical progress demands substantial capital deployment into fundamentally uncertain scientific frontiers. Late-stage trial failures for treatments targeting complex conditions like myotonic dystrophy type 1 and cardiovascular risks are standard, manageable friction in high-reward drug discovery. Market mechanisms require companies to explore high-risk clinical targets to unlock transformative therapies and future commercial value.

• Diversified Portfolio Resilience Shield Enterprise strength relies on broad asset diversification rather than single-therapy dependence. Despite consecutive pipeline setbacks, Novartis demonstrated operational resilience by reaffirming its 5% to 6% annual sales growth guidance through 2030. Positive late-stage trial results for remibrutinib in treating relapsing multiple sclerosis prove that a robust, multi-pronged pipeline effectively absorbs individual clinical losses.

• Efficient Capital Price Discovery Equity markets function correctly by rapidly repricing assets when clinical assumptions fail to materialize. The immediate 9% share price adjustment reflects efficient discipline, signaling Novartis to review data, consult regulators, and reallocate capital away from underperforming programs. Swift market feedback ensures that research expenditures are continuously optimized toward viable, scientifically sound medical treatments.

How it may affect me

As a U.S. reader:

• Patients seeking new therapies for myotonic dystrophy type 1 or specific cardiovascular conditions face delays or lack of new treatment options following the late-stage trial failures of del-desiran and pelacarsen.

• Individuals living with relapsing multiple sclerosis may see future treatment benefits following positive late-stage trial results demonstrating delayed disability progression for remibrutinib.

• Participants in experimental cell therapy trials face immediate treatment disruptions and increased safety scrutiny following the suspension of eight clinical studies due to patient deaths.

• Everyday investors with holdings or retirement funds tied to healthcare equities may experience short-term portfolio losses following the nine percent decline in company share prices.

Novartis Shares Decline Following Multiple Clinical Trial Setbacks

The BareStory

Left Perspective

Right Perspective

How it may affect me

Read the story at